Jan Skvarka Buys Shares of ZNTL $ZNTL
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jan Skvarka, insider at Zentalis Pharmaceuticals, Inc. ($ZNTL), bought 57,100 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Zentalis Pharmaceuticals, Inc. Stock Down 2.6%
Shares of Zentalis Pharmaceuticals, Inc. ($ZNTL) traded around $3.70 on Thursday, down 2.6% for the day.
Zentalis Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Get Zentalis Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZNTL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.